Development of lead inhibitors of HIV VIF binding to antiretroviral A3G through medicinal chemistry
Ended Project Grant Awarded Last action
- Award ID
- R43AI155113
- Recipient
-
Oyagen, Inc. UEI JDWRVEQGKPJ8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,145,724
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $859,293.00 Federal
- $286,431.00 Non-federal
- Place of performance
- New York, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $286,431 | $0 | |
| Amendment | $286,431 | $286,431 | |
| Original award | $286,431 | $0 |
Quick answers
Who received award R43AI155113?
R43AI155113 was awarded to Oyagen, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2020.
How much is award R43AI155113 worth?
$1,145,724 has been obligated on R43AI155113: $859,293 in federal funding and $286,431 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award